Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1-42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment

Emmanuelle Duron; Jean-Sébastien Vidal; Dominique Grousselle; Audrey Gabelle; Sylvain Lehmann; Florence Pasquier; Stéphanie Bombois; Luc Buée; Bernadette Allinquant; Susanna Schraen-Maschke; Christiane Baret; Anne-Sophie Rigaud; Olivier Hanon; Jacques Epelbaum

doi:10.3389/fnagi.2018.00297

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ_1-42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment

Front Aging Neurosci. 2018 Oct 1:10:297. doi: 10.3389/fnagi.2018.00297. eCollection 2018.

Authors

Emmanuelle Duron^{1

2

3

4}, Jean-Sébastien Vidal^{1

5}, Dominique Grousselle², Audrey Gabelle⁶, Sylvain Lehmann⁷, Florence Pasquier⁸, Stéphanie Bombois, Luc Buée⁸, Bernadette Allinquant², Susanna Schraen-Maschke⁸, Christiane Baret⁹, Anne-Sophie Rigaud^{1

5}, Olivier Hanon^{1

5}, Jacques Epelbaum^{2

10}

Affiliations

¹ AP-HP, Hôpital Broca, Service de Gériatrie, Paris, France.
² Université Sorbonne Paris Cité, UMR-S894, INSERM Université Paris Descartes, Centre de Psychiatrie et Neuroscience, Paris, France.
³ APHP, Hôpital Paul Brousse, Service de Gériatrie du Dr Karoubi, Villejuif, France.
⁴ Université Paris-Sud 11, Centre de Recherche en Épidemiologie et Santé des Population- Depression et Antidépresseurs, INSERM UMR-1178, Le Kremlin-Bicêtre, France.
⁵ Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
⁶ Memory Research and Resources Center, Gui de Chauliac Hospital, University of Montpellier, Montpellier, France.
⁷ Laboratoire de Biochimie Protéomique Clinique, CHU Montpellier, University of Montpellier, INSERM, Montpellier, France.
⁸ University of Lille, INSERM 1171, CHU, Centre Mémoire (CMRR) Distalz, Lille, France.
⁹ UF de Neurobiologie, Centre Biologie Pathologie du CHU-Lille, Lille, France.
¹⁰ MECADEV UMR 7179 CNRS, Muséum National d'Histoire Naturelle, Paris, France.

Abstract

A combination of low cerebrospinal fluid (CSF) Amyloid β_1-42 (Aβ_1-42) and high Total-Tau (T-Tau) and Phosphorylated-Tau (P-Tau) occurs at a prodromal stage of Alzheimer's disease (AD) and recent findings suggest that network abnormalities and interneurons dysfunction contribute to cognitive deficits. Somatostatin (SOM) and Neuropeptide Y (NPY) are two neuropeptides which are expressed in GABAergic interneurons with different fates in AD the former only being markedly affected. The aim of this study was to analyze CSF SOM, NPY and CSF Aβ_1-42; T-Tau, P-Tau relationships in 43 elderly mild cognitively impairment (MCI) participants from the Biomarker of AmyLoïd pepTide and AlZheimer's disease Risk (BALTAZAR) cohort. In these samples, CSF SOM and CSF Aβ_1-42 on the one hand, and CSF NPY and CSF T-Tau and P-Tau on the other hand are positively correlated. CSF SOM and NPY concentrations should be further investigated to determine if they can stand for early AD biomarkers. Clinical Trial Registration: www.ClinicalTrials.gov, identifier #NCT01315639.

Keywords: cerebrospinal fluid; mild cognitive impairment; neuropeptide Y; peptides Aβ1–42; somatostatin; tau proteins.

Associated data

ClinicalTrials.gov/NCT01315639